Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety and Treatment/Disease Burden Results from REAL 3.
Lars SavendahlTadej BattelinoMichael Højby RasmussenMeryl BrodSebastian RöhrichPaul SaengerReiko HorikawaPublished in: The Journal of clinical endocrinology and metabolism (2023)
Somapacitan showed similar efficacy and safety in patients who continued somapacitan treatment and those who switched from daily GH to somapacitan. Once-weekly injections may lead to a reduced treatment burden relative to once-daily injections. A plain language summary (1) is available for this study.